ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
SETDB1: an emerging target for anticancer drug development [Editorial] (2025)
Trossini, Gustavo Henrique Goulart ; Hassanie, Haifa ; Penteado, André Berndt ; Hajje, Marissa El
Source: Future Medicinal Chemistry. Unidade: FCF
Subjects: NEOPLASIAS, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TROSSINI, Gustavo Henrique Goulart et al. SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://dx.doi.org/10.1080/17568919.2024.2444869. Acesso em: 24 abr. 2026. , 2025
APA
Trossini, G. H. G., Hassanie, H., Penteado, A. B., & Hajje, M. E. (2025). SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1080/17568919.2024.2444869
NLM
Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2026 abr. 24 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869
Vancouver
Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2026 abr. 24 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869
Artigo de periodico
SETDB1 as a cancer target: challenges and perspectives in drug design (2024)
Hassanie, Haifa ; Penteado, André Berndt ; Almeida, Larissa Costa de ; Calil, Raisa Ludmila; Emery, Flavio da Silva ; Costa-Lotufo, Letícia Veras ; Trossini, Gustavo Henrique Goulart
Source: RSC Medicinal Chemistry. Unidades: FCFRP, ICB, FCF
Subjects: NEOPLASIAS, MEDICAMENTO, GENOMAS, CÉLULAS CULTIVADAS DE TUMOR, EPIGÊNESE GENÉTICA, CROMATINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HASSANIE, Haifa et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, v. 15, n. 5, p. 1424-1451, 2024Tradução . . Disponível em: https://dx.doi.org/10.1039/D3MD00366C. Acesso em: 24 abr. 2026.
APA
Hassanie, H., Penteado, A. B., Almeida, L. C. de, Calil, R. L., Emery, F. da S., Costa-Lotufo, L. V., & Trossini, G. H. G. (2024). SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, 15( 5), 1424-1451. doi:10.1039/D3MD00366C
NLM
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2026 abr. 24 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
Vancouver
Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2026 abr. 24 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
Artigo de periodico
Human sirtuin 2 inhibitors, their mechanisms and binding modes (2023)
Penteado, André Berndt ; Hassanie, Haifa ; Gomes, Renan Augusto ; Emery, Flavio da Silva ; Trossini, Gustavo Henrique Goulart
Source: Future Medicinal Chemistry. Unidades: FCFRP, FCF
Subjects: METABOLISMO, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PENTEADO, André Berndt et al. Human sirtuin 2 inhibitors, their mechanisms and binding modes. Future Medicinal Chemistry, v. 15, n. 3, p. 291-311, 2023Tradução . . Disponível em: https://doi.org/10.4155/fmc-2022-0253. Acesso em: 24 abr. 2026.
APA
Penteado, A. B., Hassanie, H., Gomes, R. A., Emery, F. da S., & Trossini, G. H. G. (2023). Human sirtuin 2 inhibitors, their mechanisms and binding modes. Future Medicinal Chemistry, 15( 3), 291-311. doi:10.4155/fmc-2022-0253
NLM
Penteado AB, Hassanie H, Gomes RA, Emery F da S, Trossini GHG. Human sirtuin 2 inhibitors, their mechanisms and binding modes [Internet]. Future Medicinal Chemistry. 2023 ; 15( 3): 291-311.[citado 2026 abr. 24 ] Available from: https://doi.org/10.4155/fmc-2022-0253
Vancouver
Penteado AB, Hassanie H, Gomes RA, Emery F da S, Trossini GHG. Human sirtuin 2 inhibitors, their mechanisms and binding modes [Internet]. Future Medicinal Chemistry. 2023 ; 15( 3): 291-311.[citado 2026 abr. 24 ] Available from: https://doi.org/10.4155/fmc-2022-0253
Trabalho de evento-resumo
Docking studies of the Cannabinoids derivatives in O- GlcNAc Transferase (OGT) as anti-cancer candidates (2023)
El Hajje, Marissa ; Hassanie, Haifa ; Trossini, Gustavo Henrique Goulart
Source: Anais. Conference titles: Reunião Anual da Sociedade Brasileira de Química/RASBQ. Unidade: FCF
Subjects: CANABINOIDES, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EL HAJJE, Marissa e HASSANIE, Haifa e TROSSINI, Gustavo Henrique Goulart. Docking studies of the Cannabinoids derivatives in O- GlcNAc Transferase (OGT) as anti-cancer candidates. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 24 abr. 2026.
APA
El Hajje, M., Hassanie, H., & Trossini, G. H. G. (2023). Docking studies of the Cannabinoids derivatives in O- GlcNAc Transferase (OGT) as anti-cancer candidates. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
NLM
El Hajje M, Hassanie H, Trossini GHG. Docking studies of the Cannabinoids derivatives in O- GlcNAc Transferase (OGT) as anti-cancer candidates [Internet]. Anais. 2023 ;[citado 2026 abr. 24 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Vancouver
El Hajje M, Hassanie H, Trossini GHG. Docking studies of the Cannabinoids derivatives in O- GlcNAc Transferase (OGT) as anti-cancer candidates [Internet]. Anais. 2023 ;[citado 2026 abr. 24 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf
Artigo de periodico
Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity (2022)
Rodrigues Junior, Dorival Mendes ; Raminelli, Cristiano ; Hassanie, Haifa ; Trossini, Gustavo Henrique Goulart ; Perecim, Givago Prado; Puigsubira, Laia Caja ; Moustakas, Aristidis ; Vettore, André Luiz
Source: Scientific Reports. Unidade: FCF
Subjects: NEOPLASIAS CEREBRAIS, QUIMIOTERAPIA, RADIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES JUNIOR, Dorival Mendes et al. Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity. Scientific Reports, v. 12, p. 1-17, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-25534-2. Acesso em: 24 abr. 2026.
APA
Rodrigues Junior, D. M., Raminelli, C., Hassanie, H., Trossini, G. H. G., Perecim, G. P., Puigsubira, L. C., et al. (2022). Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity. Scientific Reports, 12, 1-17. doi:10.1038/s41598-022-25534-2
NLM
Rodrigues Junior DM, Raminelli C, Hassanie H, Trossini GHG, Perecim GP, Puigsubira LC, Moustakas A, Vettore AL. Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity [Internet]. Scientific Reports. 2022 ; 12 1-17.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1038/s41598-022-25534-2
Vancouver
Rodrigues Junior DM, Raminelli C, Hassanie H, Trossini GHG, Perecim GP, Puigsubira LC, Moustakas A, Vettore AL. Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity [Internet]. Scientific Reports. 2022 ; 12 1-17.[citado 2026 abr. 24 ] Available from: https://doi.org/10.1038/s41598-022-25534-2

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies